Dydrogesterone use in early pregnancy

References

• Schindler AE. First trimester endocrinology: consequences for diagnosis and treatment of pregnancy failure. Gynecol Endocrinol 2004;18:51–7
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Barakonyi A, Par G, et al. Progesterone as an immunomodulatory molecule. Int Immunopharmacol 2001;1:1037–48
   PubMed Web of Science ®Google Scholar
• Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 2009;65:S3–S11
   PubMed Web of Science ®Google Scholar
• Blacker CM, Ginsburg KA, Leach RE, et al. Unexplained infertility: evaluation of the luteal phase; results of the National Center for Infertility Research at Michigan. Fertil Steril 1997;67:437–42
   PubMed Web of Science ®Google Scholar
• Baird DD, Wilcox AJ, Weinberg CR, et al. Preimplantation hormonal differences between the conception and non-conception menstrual cycles of 32 normal women. Hum Reprod 1997;12:2607–13
   PubMed Web of Science ®Google Scholar
• Csapo AI, Pulkkinen MO, Ruttner B, et al. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol 1972;112:1061–7
   PubMed Web of Science ®Google Scholar
• Couzinet B, Le Strat N, Ulmann A, et al. Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone). N Engl J Med 1986;315:1565–70
   PubMed Web of Science ®Google Scholar
• Spitz IM, Bardin CW. Clinical pharmacology of RU 486 – an antiprogestin and antiglucocorticoid. Contraception 1993;48:403–44
   PubMed Web of Science ®Google Scholar
• de Lignières B. Oral micronized progesterone. Clin Ther 1999;21:41–60
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Mattei A, Gojnic M, Gerli S. Progesterone and pregnancy. Curr Opin Obstet Gynecol 2005;17:598–600
   PubMed Web of Science ®Google Scholar
• Chakravarty BN, Shirazee HH, Dam P, et al. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 2005;97:416–20
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Kanová N, Biciková M. Hyperandrogenic states in pregnancy. Physiol Res 2011;60:243–52
   PubMed Web of Science ®Google Scholar
• Rižner TL, Brožic P, Doucette C, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids 2011;76:607–15
   PubMed Web of Science ®Google Scholar
• Wang MH, Baskin LS. Endocrine disruptors, genital development, and hypospadias. J Androl 2008;29:499–505
   PubMed Web of Science ®Google Scholar
• Coppola PT, Coppola M. Vaginal bleeding in the first 20 weeks of pregnancy. Emerg Med Clin North Am 2003;21:667–77
   PubMed Web of Science ®Google Scholar
• Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997;315:32–4
   PubMed Web of Science ®Google Scholar
• Qureshi NS. Treatment options for threatened miscarriage. Maturitas 2009;65:S35–S41
   Google Scholar
• Weiss JL, Malone FD, Vidaver J, et al. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004;190:745–50
   PubMed Web of Science ®Google Scholar
• Verma SK, Premi HK, Gupta TV, et al. Perinatal outcome of pregnancies complicated by threatened abortion. J Indian Med Assoc 1994;92:364–5
   PubMedGoogle Scholar
• Arck PC, Rücke M, Rose M, et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008;17:101–13
   PubMed Web of Science ®Google Scholar
• Aleman A, Althabe F, Belizán J, Bergel E. Bed rest during pregnancy for preventing miscarriage. Cochrane Database Syst Rev 2005;2:CD003576
   Google Scholar
• Devaseelan P, Fogarty PP, Regan L. Human chorionic gonadotrophin for threatened miscarriage. Cochrane Database Syst Rev 2010;5:CD007422
   Google Scholar
• Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011;12:CD005943
   PubMedGoogle Scholar
• Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009;65:S47–S50
   PubMed Web of Science ®Google Scholar
• Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 2005;97:421–5
   PubMed Web of Science ®Google Scholar
• El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas 2009;65:S43–S46
   PubMed Web of Science ®Google Scholar
• Ehrenskjöld ML, Bondo B, Weile F. [Treatment of threatened abortion with dydrogesterone]. Ugeskr Laeger 1967;129:1678–9
   PubMedGoogle Scholar
• Mistò A. [Experiences with 6-dehydro-retroprogesterone in the treatment of placental insufficiency]. Ann Ostet Ginecol Med Perinat 1967;89:102–12
   PubMedGoogle Scholar
• Czajkowski K, Sienko J, Mogilinski M, et al. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 2007;87:613–8
   PubMed Web of Science ®Google Scholar
• Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28:983–90
   PubMed Web of Science ®Google Scholar
• Vincze E, Molnár-G B, Földesi I, Pál A. Treatment possibilities for threatened abortion using progesterone and progesterone-type drugs. Magyar Noorvosok Lapja 2006;69:281–4
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Ectopic pregnancy and miscarriage. Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage . 2012 Dec. Available from: https://www.nice.org.uk/guidance/cg154/resources/guidance-ectopic-pregnancy-and-miscarriage-pdf [last accessed 24 Aug 2015]
   Google Scholar
• The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Progesterone support of the luteal phase and in the first trimester. 13 A.D. Jul. Available from: http://www.ranzcog.edu.au/doc/progesterone-support-of-the-luteal-phase-and-early-pregnancy.html [last accessed 24 Aug 2015]
   Google Scholar
• Schindler AE, Carp H, Druckmann R, et al. European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol Endocrinol 2015;31:447–9
   PubMed Web of Science ®Google Scholar
• Arab H, Alsofayan H, Alharbi A, et al. The Saudi Obstetrics and Gynecological Society (SOGS) National Guidelines for the Prevention and Treatment of Miscarriage. Saudi J Obstet Gynecol 2014;15:40–64
   Google Scholar
• Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2013;99:63
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists. The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage. Green-top Guideline No. 17. 2011 Apr. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf [last accessed 24 Aug 2015]
   Google Scholar
• Garrido-Gimenez C, Alijotas-Reig J. Recurrent miscarriage: causes, evaluation and management. Postgrad Med J 2015;91:151–62
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006;21:2216–22
   PubMed Web of Science ®Google Scholar
• El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005;97:431–4
   PubMed Web of Science ®Google Scholar
• MacDonald RR, Goulden R, Oakey RE. Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstet Gynecol 1972;40:394–402
   PubMed Web of Science ®Google Scholar
• Kumar A, Begum N, Prasad S, et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014;102:1357–63
   PubMed Web of Science ®Google Scholar
• Ghosh S, Chattopadhyay R, Goswami S, et al. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. J Obstet Gynaecol Res 2014;40:1871–6
   PubMed Web of Science ®Google Scholar
• Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015;31:422–30
   PubMed Web of Science ®Google Scholar
• Freedman RS, Berry A. Progesterone deficiency in preganancy. S Afr J Obstet Gynaecol 1970;46:72–6
   Google Scholar
• Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2013;10:CD003511
   PubMed Web of Science ®Google Scholar
• El-mashad AI, Mohamed MA, Farag MA, et al. Role of uterine artery Doppler velocimetry indices and plasma adrenomedullin level in women with unexplained recurrent pregnancy loss. J Obstet Gynaecol Res 2011;37:51–7
   PubMed Web of Science ®Google Scholar
• Coomarasamy A, Williams H, Truchanowicz E, et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med 2015;373:2141–8
   PubMed Web of Science ®Google Scholar
• Abbott B.V. Duphaston 10mg Film-Coated Tablets Summary of Product Characteristics; 2012
   Google Scholar
• Bulletti C, de Ziegler D, Flamigni C, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997;12:1073–9
   PubMed Web of Science ®Google Scholar
• Choi TY, Lee HM, Park WK, et al. Spontaneous abortion and recurrent miscarriage: a comparison of cytogenetic diagnosis in 250 cases. Obstet Gynecol Sci 2014;57:518–25
   PubMedGoogle Scholar
• Practice Committee of the American Society for Reproductive Medicine. Current clinical irrelevance of luteal phase deficiency: a committee opinion. Fertil Steril 2015;103:e27–e32
   PubMed Web of Science ®Google Scholar
• Balasch J, Vanrell JA, Márquez M, et al. Dehydrogesterone versus vaginal progesterone in the treatment of the endometrial luteal phase deficiency. Fertil Steril 1982;37:751–4
   PubMed Web of Science ®Google Scholar
• Gidley-Baird AA, O'Neill C, Sinosich MJ, et al. Failure of implantation in human in vitro fertilization and embryo transfer patients: the effects of altered progesterone/estrogen ratios in humans and mice. Fertil Steril 1986;45:69–74
   PubMed Web of Science ®Google Scholar
• van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015;7:CD009154
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Lessing JB, Amit A, et al. A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer. Hum Reprod 1990;5:271–3
   PubMed Web of Science ®Google Scholar
• Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol 2007;23:68–72
   PubMed Web of Science ®Google Scholar
• Ganesh A, Chakravorty N, Mukherjee R, et al. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 2011;95:1961–5
   PubMed Web of Science ®Google Scholar
• Salehpour S, Tamimi M, Saharkhiz N. Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): a randomized clinical trial. Iran J Reprod Med 2013;11:913–8
   PubMed Web of Science ®Google Scholar
• Tomic V, Tomic J, Klaic DZ, et al. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2015;186:49–53
   PubMed Web of Science ®Google Scholar
• van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011;10:CD009154
   PubMed Web of Science ®Google Scholar
• Podzolkova N, Tatarchuk T, Doshchanova A, et al. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol 2015. [Epub ahead of print]. doi: 10.3109/09513590.2015.1115832
   PubMedGoogle Scholar
• Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev 2009;85:375–7
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency (MHRA). MHRA UK Public Assessment Report. Efficacy of progestogens in the maintenance of early pregnancy in women with threatened miscarriage or recurrent miscarriage. 2008 Feb. Available from: http://www.mhra.gov.uk/home/groups/s-par/documents/websiteresources/con079333.pdf [last accessed 24 Aug 2015]
   Google Scholar